Comprehensive Investigation of Natural Ligands as Inhibitors of β Secretase to Identify Alzheimer's Disease Therapeutics

被引:0
|
作者
Kushwah, Shikha [1 ]
Mani, Ashutosh [1 ]
机构
[1] Motilal Nehru Natl Inst Technol Allahabad, Dept Biotechnol, Prayagraj 211004, India
关键词
Alzheimer's disease; BACE1; amyloid-beta hypothesis; molecular docking; MD (molecular dynamics) simulation; herbal compounds; AMYLOID HYPOTHESIS; BACE1; PATHOGENESIS; PREDICTIONS; CURCUMIN; DOCKING;
D O I
10.2174/0115672050323622240705043337
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Alzheimer's disease (AD) is an alarmingly prevalent worldwide neurological disorder that affects millions of people and has severe effects on cognitive functions. The amyloid hypothesis, which links AD to A beta (amyloid beta) plaque aggregation, is a well-acknowledged theory. The beta-secretase (BACE1) is the main cause of A beta production, which makes it a possible target for therapy. FDA-approved therapies for AD do exist, but none of them explicitly target BACE1, and their effectiveness is constrained and accompanied by adverse effects.Materials and Methods We determined the essential chemical components of medicinal herbs by conducting a thorough literature research for BACE1. Computational methods like molecular docking, ADMET (Absorption, distribution, metabolism, excretion, toxicity) screening, molecular dynamic simulations, and MMPBSA analysis were performed in order to identify the most promising ligands for beta-secretase.Results The results suggested that withasomniferol, tinosporide, and curcumin had better binding affinity with BACE1, suggesting their potential as therapeutic candidates against Alzheimer's disease.Conclusion Herbal therapeutics have immense applications in the treatment of chronic diseases like Alzheimer's disease, and there is an urgent need to assess their efficacy as therapeutics.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Secretase inhibitors as therapeutics for Alzheimer's disease
    Olson, RE
    Thompson, LA
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 35, 2000, 35 : 31 - 40
  • [2] Engineered heparins:: Novel β-secretase inhibitors as potential Alzheimer's disease therapeutics
    Patey, S. J.
    Edwards, E. A.
    Yates, E. A.
    Turnbull, J. E.
    NEURODEGENERATIVE DISEASES, 2008, 5 (3-4) : 197 - 199
  • [3] γ-Secretase inhibitors and Alzheimer's disease
    Roberts, SB
    ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (12) : 1579 - 1588
  • [4] Secretase inhibitors for Alzheimer's disease
    Kornilova, AY
    Wolfe, MS
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 38, 2003, 38 : 41 - 50
  • [5] Gamma secretase inhibitors as potential Alzheimer's therapeutics.
    Churcher, I
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U968 - U968
  • [6] Untangling Alzheimer's disease with β-secretase inhibitors
    Dorrell, S
    DRUG DISCOVERY TODAY, 2000, 5 (08) : 316 - 317
  • [7] ?-Secretase inhibitors and modulators for Alzheimer's disease
    Wolfe, Michael S.
    JOURNAL OF NEUROCHEMISTRY, 2012, 120 : 89 - 98
  • [8] γ-Secretase Inhibitors for the Treatment of Alzheimer's Disease
    Wu, Wen-Lian
    Zhang, Lili
    DRUG DEVELOPMENT RESEARCH, 2009, 70 (02) : 94 - 100
  • [9] Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease
    Olson, Richard E.
    Marcin, Lawrence R.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 42, 2007, 42 : 27 - 47
  • [10] Prospects of -Secretase Inhibitors for the Treatment of Alzheimer's Disease
    Ghosh, Arun K.
    Tang, Jordan
    CHEMMEDCHEM, 2015, 10 (09) : 1463 - 1466